We estimate safe screening intervals for sight-threatening diabetic retinopathy (STDR).
Methods:
A 6-year retrospective follow-up study to review screening results of two cohorts of patients with diabetes mellitus (DM) was conducted; a cohort free of diabetic retinopathy (DR) and a cohort with mild nonproliferative diabetic retinopathy (NPDR) at baseline. Patients had been screened by means of a nonmydriatic retinal camera. Baseline age, sex, and diabetes characteristics were also collected. Statistical analysis was based on life-table method of risk estimation.
Results:
A total of 286 patients with DM free of DR and 144 patients with mild NPDR at baseline were included in the study. For patients free of DR, the probability of remaining free of STDR was 97% (95% confidence interval [CI] 94–99%) at the end of the fourth year. In this cohort of patients, those with type 2 DM were more likely to progress to STDR than those who had type 1 DM (p < .01). For patients with mild NPDR, the probability of remaining free of STDR dropped to 94% (95% CI 88–97%) at the end of the second year, and it was still 100% at the end of the second year for those with a glycated hemoglobin level ≤7.5% at baseline (p < .05).
Conclusions:
Screening at a 3–4 year interval for diabetes patients free of DR is safe because of their low risk of developing STDR. Patients with mild NPDR require screening at a 1 year interval, or at a 2 year interval with good metabolic control.
Diabetic Retinopathy Study Research Group. Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol.1976;81 (4): 383–96.
2.
WitkinSRKleinR. Ophthalmologic care for persons with diabetes. JAMA.1984;251 (19): 2534–7.
3.
Soto-PedreEHernaez-OrtegaMCPiniésJA. Duration of diabetes and screening coverage for retinopathy among patients with type 2 diabetes. Ophthalmic Epidemiol.2007;14 (2): 76–9.
4.
Soto-PedreEHernaez-OrtegaMC. Screening coverage for diabetic retinopathy using a three-field digital non-mydriatic fundus camera. Prim Care Diabetes.2008;2 (3): 141–6.
5.
StefánssonEBekTPortaMLarsenNKristinssonJKAgardhE. Screening and prevention of diabetic blindness. Acta Ophthalmol Scand.2000;78 (4): 374–85.
6.
American Diabetes Association Clinical Practice Recommendations 2001. Diabetes Care.2001;24 (Suppl 1): S1–133.
7.
Retinopathy Working Party. A protocol for screening for diabetic retinopathy in Europe. Diabet Med.1991;8 (3): 263–7.
8.
YounisNBroadbentDMVoraJPHardingSP, Liverpool Diabetic Eye Study. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet.2003;361 (9353): 195–200.
9.
YounisNBroadbentDMHardingSPVoraJP. Incidence of sight threatening retinopathy in type 1 diabetes in a systematic screening programme. Diabet Med.2003;20 (9): 758–65.
10.
VijanSHoferTPHaywardRA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA.2000;283 (7): 889–96.
11.
Hernáez-OrtegaMCSoto-PedreEVázquezJAGutiérrezMAAsúaJ. Estudio de la eficiencia de una cámara de retina nomidriática en el diagnóstico de retinopatía diabética. Rev Clin Esp.1998;198 (4): 194–9.
12.
World Medical Association. Declaration of Helsinki: ethical principles for research involving human subjects (as amended in Tokyo). Ferney-Voltaire: World Medical Association; 2004.
13.
WilkinsonCPFerrisFLIIIKleinRELeePPAgardhCDDavisMDillsDKampikAPararajasegaramRVerdaguerJT, Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular oedema disease severity scales. Ophthalmology.2003;110 (9): 1677–82.
14.
SnedecorGWCochranWG. Statistical methods. 8th ed.Ames: Iowa State University Press; 1989.
15.
CoxDROakesD. Analysis of survival data. London: Chapman & Hall; 1984.
16.
KleinRMeuerSMMossSEKleinBE. Retinal microaneurysm counts and 10-year progression of diabetic retinopathy. Arch Ophthalmol.1995;113 (11): 1386–91.
17.
KleinRKleinBEMossSECruickshanksKJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology.1998;105 (10): 1801–15.
18.
ZhangLKrzentowskiGAlbertALefebvrePJ. Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care.2001;24 (7): 1275–9.
19.
PortaMSjoelieAKChaturvediNStevensLRottiersRVeglioMFullerJH, EURODIAB Prospective Complications Study Group. Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study. Diabetologia.2001;44 (12): 2203–9.
20.
KeenHLeeETRussellDMikiEBennettPHLuM. The appearance of retinopathy and progression to proliferative retinopathy: the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia.2001;44Suppl 2: S22–30.
21.
StrattonIMKohnerEMAldingtonSJTurnerRCHolmanRRManleySEMatthewsDR. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia.2001;44 (2): 156–63.
22.
Lövestam-AdrianMAgardhCDTorffvitOAgardhE. Diabetic retinopathy, visual acuity, and medical risk indicators: a continuous 10-year follow-up study in type 1 diabetic patients under routine care. J Diabetes Complications.2001;15 (6): 287–94.
23.
HenricssonMNyströmLBlohméGOstmanJKullbergCSvenssonMSchölinAArnqvistHJBjörkEBolinderJErikssonJWSundkvistG. The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care.2003;26 (2): 349–54.
24.
LookerHCKrakoffJKnowlerWCBennettPHKleinRHansonRL. Longitudinal studies of incidence and progression of diabetic retinopathy assessed by retinal photography in Pima Indians. Diabetes Care.2003;26 (2): 320–6.
25.
van LeidenHADekkerJMMollACNijpelsGHeineRJBouterLMStehouwerCDPolakBC. Risk factors for incident retinopathy in a diabetic and nondiabetic population: the Hoorn study. Arch Ophthalmol.2003;121 (2): 245–51.
26.
SloanFABrownDSCarlisleESOstermannJLeePP. Estimates of incidence rates with longitudinal claims data. Arch Ophthalmol.2003;121 (10): 1462–8.
27.
MatthewsDRStrattonIMAldingtonSJHolmanRRKohnerEM, U.K. Prospective Diabetes Study Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol.2004;122 (11): 1631–40.
28.
TappRJZimmetPZHarperCAMcCartyDJChitsonPTonkinAMSöderbergSTaylorHRAlbertiKGTuomilehtoJShawJE. Six year incidence and progression of diabetic retinopathy: results from the Mauritius diabetes complication study. Diabetes Res Clin Pract.2006;73 (3): 298–303.
29.
RoyMSAffoufM. Six-year progression of retinopathy and associated risk factors in African American patients with type 1 diabetes mellitus: the New Jersey 725. Arch Ophthalmol.2006;124 (9): 1297–306.
30.
TamVHLamEPChuBCTseKKFungLM. Incidence and progression of diabetic retinopathy in Hong Kong Chinese with type 2 diabetes mellitus. J Diabetes Complications.2009;23 (3): 185–93.
31.
ÓlafsdóttirEStefánssonE. Biennal eye screening in patients with diabetes without retinopathy: 10-year experience. Br J Ophthalmol.2007;91 (12): 1599–601.
32.
FongDSGottliebJFerrisFLIIIKleinR. Understanding the value of diabetic retinopathy screening. Arch Ophthalmol.2001;119 (5): 758–60.
33.
KleinR. Screening interval for retinopathy in type 2 diabetes. Lancet.2003;361 (9353): 190–1.
34.
National Diabetes Data Group. Diabetes in America. 2nd ed.Bethesda: National Institutes of Health; 1995.
35.
McKayRMcCartyCATaylorHR. Diabetic retinopathy in Victoria, Australia: the Visual Impairment Project. Br J Ophthalmol.2000;84 (8): 865–70.
36.
TappRJShawJEHarperCAde CourtenMPBalkauBMcCartyDJTaylorHRWelbornTAZimmetPZ, AusDiab Study Group. The prevalence of and factors associated with diabetic retinopathy in the Australian Population. Diabetes Care.2003;26 (6): 1731–7.
37.
VarmaRTorresMPeñaFKleinRAzenSP, Los Angeles Latino Eye Study Group. Prevalence of diabetic retinopathy in adult Latinos: the Los Angeles Latino eye study. Ophthalmology.2004;111 (7): 1298–306.
38.
U.K. Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet.1998;352 (9131): 837–53.
39.
PhiriRKeeffeJEHarperCATaylorHR. Comparative study of the Polaroid and digital non-mydriatic cameras in the detection of referrable diabetic retinopathy in Australia. Diabet Med.2006;23 (8): 867–72.
